BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld Asia
Home
» FDA hits pause on Kolon's phase III Invossa-K trial for false ingredient claim
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
FDA hits pause on Kolon's phase III Invossa-K trial for false ingredient claim
May 15, 2019
By
Jihyun Kim
No Comments
HONG KONG – Kolon Tissuegene Inc., of Rockville, Md., has been ordered by the U.S. FDA to halt the phase III trial of its osteoarthritis cell and gene therapy, Invossa-K, as cancerous cell lines might have been used making the product.
BioWorld Asia